BAC
Bank of America Corporation
BAC has the edge over CNS overall, supported by stronger fundamentals and stronger modeled upside.
CNS
Cohen & Steers, Inc.
CNS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CNS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CNS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNS.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CNS in the historical PE scenario, which offers more potential upside but is not a forecast.
CNS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $60.37 | -15% |
| Forward | 20x | $71.42 | — |
| Current | 22x | $71.42 | — |
| Fair | 25x | $80.45 | +13% |
| Expensive | 32x | $105 | +47% |
Historical ranges are pointers, not guarantees.
CNS's PE is in its fair range at 22x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CNS on the outlook, with more favorable revenue expectations.
CNS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNS's earnings to grow and its profitability to improve, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CNS on earnings, with more consistent year-over-year improvement.
CNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.64 | +12% |
| Q3 2026 | $3.25 | +1.9% |
| Q2 2026 | $3.25 | +3.2% |
| Q1 2026 | $3.02 | -1.3% |
| Q4 2025 | $2.97 | 0% |
| Q3 2025 | $3.19 | +19% |
| Q2 2025 | $3.15 | +23% |
| Q1 2025 | $3.06 | +19% |
| Q4 2024 | $2.97 | +14% |
CNS earned $3.25 per share over the past year, up 1.9% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over CNS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
CNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $157.4M | +11% |
| Q2 2026 | $152.7M | +12% |
| Q1 2026 | $145.6M | +8.3% |
| Q4 2025 | $143.8M | +2.9% |
| Q3 2025 | $141.7M | +6.4% |
| Q2 2025 | $136.1M | +12% |
| Q1 2025 | $134.5M | +9.6% |
| Q4 2024 | $139.8M | +17% |
CNS's revenue has grown year over year for 10 quarters in a row: $157M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -2.1 points |
| Q2 2026 | 35% | +2.7 points |
| Q1 2026 | 34% | +0.8 points |
| Q4 2025 | 28% | -7.3 points |
| Q3 2025 | 35% | +0.8 points |
| Q2 2025 | 32% | +0.3 points |
| Q1 2025 | 34% | +0.8 points |
| Q4 2024 | 35% | +3.5 points |
CNS has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the stronger cash trend. Its trailing FCF is up 119% versus its history, compared with CNS at down 71%.
CNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20M | -62% |
| Q1 2026 | -$51.4M | +$58.7M |
| Q4 2025 | $776K | -98% |
| Q3 2025 | $52.6M | +117% |
| Q2 2025 | -$69.8M | -357% |
| Q1 2025 | -$110M | -20588% |
| Q4 2024 | $33.1M | -31% |
| Q3 2024 | $24.2M | -50% |
CNS's free cash flow was $22M over the past year, against −$122M the year before. Free cash flow isn't a meaningful measure for financial services companies like CNS.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CNS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +253K shares |
| 1 year | +1.1% | +542K shares |
| 3 years | +5% | +2.5M shares |
| 5 years | +5.8% | +2.9M shares |
| Available history | +7% | +3.4M shares |
CNS has 52M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $358,000 |
| Q2 2026 | $394,000 |
| Q1 2026 | $16.9M |
| Q4 2025 | $1.6M |
| Q3 2025 | $258,000 |
| Q2 2025 | $621,000 |
| Q1 2025 | $26M |
| Q4 2024 | $1.5M |
CNS spent $19M buying back its own shares over the past year, down 32% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CNS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
CNS has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.8 | Neutral |
| Stochastic | 33.9 | Neutral |
CNS's weekly RSI is 45 (neutral) and its Stochastic is 34 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over CNS on valuation relative to its sector.
CNS PE vs Financial Services Sector
| Metric | CNS | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 69% above |
| PE % | 33 | 63 | 30 pts below |
CNS is trading at 22x earnings, a 69% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 0.5% below |
| 20 week MA | $77.0 | 7.2% below |
| 50 week MA | $71.1 | 0.4% above |
| 100 week MA | $74.1 | 3.6% below |
| 200 week MA | $73.1 | 2.3% below |
CNS's trend is mixed: it's above one of its five weekly moving averages, and 2.3% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
CNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.7 | $73.4 | +17% |
| 2021 | $73.4 | $90.0 | +23% |
| 2022 | $90.0 | $63.2 | -30% |
| 2023 | $63.2 | $75.7 | +20% |
| 2024 | $75.7 | $93.4 | +23% |
| 2025 | $93.4 | $64.2 | -31% |
| 2026 YTD | $64.2 | $71.4 | +11% |
CNS has the edge over BAC on returns for 2026, with the stronger performance.